Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications

Jie, Xiaoxiang; Zhang, Xiaoyan; Xu, Congjian

doi:10.18632/oncotarget.18277

Cited by 154 publications

(131 citation statements)

References 136 publications

Supporting

Mentioning

127

Contrasting

Order By: Relevance

“…Other potential markers such as CD133, one of the cancer stem cell markers have been employed for mesenchymal‐like CTCs isolation methods . There are many reports indicating that CTCs expressing high levels of EMT markers in several cancer types such as breast, prostate, and colorectal, are often accompanied by the expression of cancer stem cell markers, suggesting the utility of incorporating stem cell markers such as CD133 . However, the relationship between EMT markers and CD133 on CTCs in lung cancer is not well‐understood.…”

Section: Discussionmentioning

confidence: 99%

“…40 There are many reports indicating that CTCs expressing high levels of EMT markers in several cancer types such as breast, prostate, and colorectal, are often accompanied by the expression of cancer stem cell markers, suggesting the utility of incorporating stem cell markers such as CD133. [47][48][49] However, the relationship between EMT markers and CD133 on CTCs in lung cancer is not well-understood. Potential of other EMT markers including CD133 to detect mesenchymal-like CTCs should be pursued in the future, nonetheless.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

et al. 2020

View full text Add to dashboard Cite

Noninvasive diagnostics using circulating tumor cells (CTCs) are expected to be useful for decision making in precision cancer therapy. AXL, a receptor tyrosine kinase is associated with tumor progression, epithelial‐to‐mesenchymal transition (EMT), and drug resistance, and is a potential therapeutic target. However, the epithelial markers generally used for CTC detection may be not enough to detect AXL‐expressing CTCs due to EMT. Here, we evaluated the detection of AXL‐expressing CTCs using the mesenchymal marker vimentin with a microcavity array system. To evaluate the recovery of cancer cells, spike‐in experiments were performed using cell lines with varying cytokeratin (CK) or vimentin (VM) expression levels. With high CK and low VM‐expressing cell lines, PC‐9 and HCC827, the recovery rate of AXL‐expressing cancer cells was 1%‐17% using either CK or VM as markers. Whereas, with low CK and high VM‐expressing cell lines, MDA‐MB231 and H1299, it was 52%‐75% using CK and 72%‐88% using VM as a marker. For clinical evaluation, peripheral blood was collected from 20 non–small cell lung cancer patients and CTCs were detected using CK or VM as markers in parallel. Significantly more AXL‐expressing single CTCs were detected in VM‐positive than CK‐positive CTCs (P < .001). Furthermore, CTC clusters were identified only among VM‐positive CTCs in 20% of patients. Patients with one or more prior treatments harbored significantly more VM‐positive AXL‐expressing CTCs, suggesting the involvement of these CTCs in drug resistance. These results indicate the necessity of integrating mesenchymal markers with CTC detection and this should be further evaluated clinically.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These factors often influence the expression of each other, frequently converge in the regulation of common target genes and in general upregulate mesenchymal genes and repress epithelial genes [6,120,121,133,134]. SNAIL1 and SNAIL2, also known as SNAIL and SLUG, respectively, activate the EMT program [6,133,135,136,137,138,139,140,141,142,143,144].…”

Section: Epithelial-mesenchymal Transition (Emt)mentioning

confidence: 99%

Molecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers

Cevenini

Orrú

Mancini

et al. 2018

IJMS

View full text Add to dashboard Cite

The insulin-like growth factor (IGF) system, which is constituted by the IGF-1 and IGF-2 peptide hormones, their corresponding receptors and several IGF binding proteins, is involved in physiological and pathophysiological processes. The IGF system promotes cancer proliferation/survival and its signaling induces the epithelial-mesenchymal transition (EMT) phenotype, which contributes to the migration, invasiveness, and metastasis of epithelial tumors. These cancers share two major IGF-1R signaling transduction pathways, PI3K/AKT and RAS/MEK/ERK. However, as far as we could review at this time, each type of cancer cell undergoes EMT through tumor-specific routes. Here, we review the tumor-specific molecular signatures of IGF-1-mediated EMT in breast, lung, and gastric cancers.

show abstract

“…Jie et al [6]* worked out the important problem of the still debated involvement of the epitelial-to-mesenchymental transition (EMT) in metastasis. EMT contributes to the generation of CTCs in epithelial cancers because it increases tumor cells invasiveness, promotes tumor cell intravasation and ensures tumor cell survival in the peripheral system.…”

Section: Liquid Biopsy Through Viable Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Cancer-Devoted Liquid Biopsies and Applications to Prostate Cancer

Tatischeff¹

2018

J Neoplasm

View full text Add to dashboard Cite

Human Prostate cancer (PCa), the second most frequent in men, is facing two yet unsolved problems: first, at diagnosis, the prostate-specific antigen (PSA) blood test is not specific enough, which results in too much false positive detection; secondly, at the last tumor step, the metastatic castration-resistant prostate cancer (CRPC) is of very bad survival prognosis. Therefore, tools are urgently needed for helping the active surveillance before any treatment and for monitoring treatment of advanced prostate cancer for trying to slow down the fatal issue. This survey corresponds to a pertinent -but not completeselection among many recent papers, searched in PubMed and Web of Science with the keywords "Liquid Biopsy" and "Prostate Cancer". It is aimed to give an overview of the existing methods searching for a satisfying reliable clinical test, i. e. obtained from easy accessible bodyfluids such as blood or urine, in order to replace the invasive needle tissue biopsies for frequent therapeutic control of PCa development. Taking into account the huge heterogeneity of the tumor process, elaborating a convenient liquid biopsy is also a necessary step towards a further individually-adapted precision medicine for curing prostate cancer. The most promising perspectives for clinical analysis of PCa through liquid biopsy will be discussed.

show abstract

Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications

Abstract: Epithelial-to-mesenchymal transition (EMT) endows

Cited by 154 publications

References 136 publications

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system

Molecular Signatures of the Insulin-like Growth Factor 1-mediated Epithelial-Mesenchymal Transition in Breast, Lung and Gastric Cancers

Cancer-Devoted Liquid Biopsies and Applications to Prostate Cancer

Contact Info

Product

Resources

About